The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
ACADEMIA
Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
Conducting comprehensive genomic profiling (CGP) tests before initiating first-line drug therapy reduced the risk of death by 41% in cancer patients, according to observational study data reported by Kyoto University Hospital on November 28. Manabu Muto, professor at the hospital…
To read the full story
Related Article
- Few Testing Facilities, Timing of Coverage Pose Challenge in CGP Testing in Japan: Oncologist
February 27, 2025
- Oncologist Sees Need to Seek Middle Ground towards CGP Testing for 1st Line Therapy
February 17, 2025
- Trade Groups, Academic Societies Urge Govt to Expand Coverage for CGP Testing
December 26, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- CGP Assays Prior to Initial Treatment Would Have Little Impact on Health Finances: Professor
May 31, 2023
- MHLW Panel OKs Research Report That Could Set Stage for Gene Profiling Before 1st-Line Cancer Therapy
March 15, 2023
ACADEMIA
- Japan’s Maternal RSV Vaccine Uptake at 11.6%, Survey Finds
January 15, 2026
- Early CGP Testing Cuts Mortality Risk by 41%, Research Shows
December 1, 2025
- 5-Year Cancer Survival Shows Wide Gap by Tumor Types, Gains Seen in Lymphoma: NCC
November 20, 2025
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…